The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant pembrolizumab demonstrated significant overall-survival improvement in patients with ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...

Cash receipts from customers in Q1 FY25 were $20k. During the quarter, Immutep received a €2,194,918 (~A$3,602,362) research ...